Actively Recruiting
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population
Led by AstraZeneca · Updated on 2026-03-27
850
Participants Needed
12
Research Sites
176 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory/immunological mechanisms on early COPD, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants initially for 1-year period. The follow-up period may extend up to 3 years depending upon emerging data and feasibility assessment by the sponsor.
CONDITIONS
Official Title
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Capable of giving signed informed consent form
- Able to perform acceptable lung function testing for FEV1 according to American Thoracic Society and European Respiratory Society 2019 criteria
- Able and willing to comply with all study requirements including completing questionnaires in the translated language
- Allowed to enroll in other studies with permission from the Steering Committee
You will not qualify if you...
- History of alcohol or drug abuse within the past year that contraindicates participation
- Altered mental status at the time of informed consent
- Clinically significant abnormal vital signs, ECG, or lab results that could interfere with study or safety
- Current diagnosis of asthma or asthma-COPD overlap; childhood asthma resolved before age 18 is allowed
- Significant lung diseases other than COPD such as active infection, bronchiectasis, fibrosis, cystic fibrosis, lung cancer, alpha-1 anti-trypsin deficiency, or primary ciliary dyskinesia
- COPD exacerbation within 2 weeks prior to enrollment treated with systemic corticosteroids, antibiotics, or hospitalization
- History of lung resection or lung volume reduction surgery within 6 months or planned during study
- Unstable autoimmune, metabolic, or cardiovascular disorders
- Current or recent malignancy within 5 years except treated non-invasive skin or cervical carcinoma
- Terminal disease or organ failure making participation inappropriate
- Receipt of investigational biologics within 3 months or 5 half-lives before enrollment
- Active participation in another interventional clinical trial
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Research Site
Beijing, China
Not Yet Recruiting
2
Research Site
Changsha, China
Not Yet Recruiting
3
Research Site
Chengdu, China
Not Yet Recruiting
4
Research Site
Guangzhou, China
Actively Recruiting
5
Research Site
Hefei, China
Not Yet Recruiting
6
Research Site
Nanjing, China
Not Yet Recruiting
7
Research Site
Nanning, China
Not Yet Recruiting
8
Research Site
Shanghai, China
Not Yet Recruiting
9
Research Site
Shenyang, China
Not Yet Recruiting
10
Research Site
Wuhan, China
Not Yet Recruiting
11
Research Site
Xuzhou, China
Not Yet Recruiting
12
Research Site
Zhengzhou, China
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here